Can tapering tocilizumab prevent relapse in giant cell arteritis?
NCT ID NCT06037460
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This study looks at the best way to stop tocilizumab in people with giant cell arteritis, a condition that causes inflamed blood vessels. About 120 participants will either stop the drug suddenly or taper it gradually. The goal is to see which approach lowers the chance of relapse and reduces the need for steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chu Dijon Bourgogne
Dijon, 21000, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab
What this could lead to
If successful, this could show that tapering tocilizumab lowers relapse rates, helping doctors manage giant cell arteritis more safely and cost-effectively.
What could go wrong
This is a phase 3 trial, but results may not apply to all patients. Relapse risk remains around 40% after stopping, and monitoring disease activity is challenging due to tocilizumab's effects on standard blood tests.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.